SEP owns worldwide rights to Bulkamid, a class leading urethral bulking agent used in the treatment of stress urinary incontinence. More than 30,000 people have been treated to date with a procedure that is performed under endoscopic control using the Bulkamid Urethral Bulking System.
SEP owns worldwide rights to Mitem/Mitocin (mitomycin), a cytotoxic medicine used in the treatment of a variety of cancers, including bladder cancer. Mitomycin has been on the market for many years and represents the standard treatment for patients with superficial risk bladder cancer.
SEP has distribution rights in the UK and the Republic of Ireland for Regurin XL and Regurin BD, respectively once daily and twice daily treatments for overactive bladder. Regurin XL is rapidly becoming the treatment of choice of many doctors due to its impressive clinical results.
SEP owns worldwide rights to Aquamid, an aesthetic injectable volumiser. Plastic surgeons, dermatologists and cosmetic physicians have treated more than a quarter of a million people with Aquamid so far. Aquamid is available through a network of distributors covering 40 countries.